Compare API & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | API | NNNN |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 340.2M |
| IPO Year | 2020 | 2023 |
| Metric | API | NNNN |
|---|---|---|
| Price | $4.39 | $5.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.4K | ★ 252.4K |
| Earning Date | 05-26-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | N/A |
| P/E Ratio | ★ $92.30 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $5.13 |
| 52 Week High | $5.50 | $51.33 |
| Indicator | API | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 29.08 |
| Support Level | $3.96 | N/A |
| Resistance Level | $4.31 | $12.10 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 79.41 | 23.43 |
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).